Karyopharm Therapeutics (KPTI) Aperçu de l'action
Karyopharm Therapeutics Inc. est une société pharmaceutique au stade commercial qui découvre, développe et commercialise des médicaments dirigés contre l'exportation nucléaire pour le traitement du cancer et d'autres maladies aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
KPTI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Karyopharm Therapeutics Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$10.21 |
| Plus haut sur 52 semaines | US$10.99 |
| Plus bas sur 52 semaines | US$3.65 |
| Bêta | 0.82 |
| Variation sur 1 mois | 13.70% |
| Variation sur 3 mois | 86.31% |
| Variation sur 1 an | 132.57% |
| Variation sur 3 ans | -61.97% |
| Variation sur 5 ans | -93.52% |
| Évolution depuis l'introduction en bourse | -95.76% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jun 24
KPTI: Phase 3 Myelofibrosis Data Will Shape 2026 Risk Reward Profile
Analysts have adjusted their outlook on Karyopharm Therapeutics with a revised consensus price target, reflecting shifts in recent $5 and $8 upward revisions and $7 and $4 downward revisions as they reassess the company's risk profile and long term earnings potential. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a split view, with some firms revising price targets upward and others marking them down.Seeking Alpha • Jun 18
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell
Summary Karyopharm Therapeutics receives a reiterated Sell rating due to persistent clinical and commercial challenges with selinexor (Xpovio). Xpovio revenues remain stagnant at $115 million, with ongoing toxicity and competition issues undermining growth and adoption. Recent Phase 3 SENTRY trial results for selinexor in myelofibrosis were mixed, missing key symptom improvement endpoints and highlighting severe adverse events. KPTI faces a thin balance sheet, ongoing cash burn, high dilution risk, and a pipeline still heavily reliant on selinexor with limited near-term catalysts. Read the full article on Seeking AlphaMise à jour du récit • Jun 07
KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline Opportunity
Analysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.Recent updates
Mise à jour du récit • Jun 24
KPTI: Phase 3 Myelofibrosis Data Will Shape 2026 Risk Reward Profile
Analysts have adjusted their outlook on Karyopharm Therapeutics with a revised consensus price target, reflecting shifts in recent $5 and $8 upward revisions and $7 and $4 downward revisions as they reassess the company's risk profile and long term earnings potential. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a split view, with some firms revising price targets upward and others marking them down.Seeking Alpha • Jun 18
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell
Summary Karyopharm Therapeutics receives a reiterated Sell rating due to persistent clinical and commercial challenges with selinexor (Xpovio). Xpovio revenues remain stagnant at $115 million, with ongoing toxicity and competition issues undermining growth and adoption. Recent Phase 3 SENTRY trial results for selinexor in myelofibrosis were mixed, missing key symptom improvement endpoints and highlighting severe adverse events. KPTI faces a thin balance sheet, ongoing cash burn, high dilution risk, and a pipeline still heavily reliant on selinexor with limited near-term catalysts. Read the full article on Seeking AlphaMise à jour du récit • Jun 07
KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline Opportunity
Analysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.
Mise à jour du récit • May 03
KPTI: Selinexor Commercialization And Funding Pressures Will Likely Constrain Future Upside
Analyst price targets for Karyopharm Therapeutics have shifted, with recent cuts and a subsequent $8 increase tied to reassessments of revenue potential, profit margins and future P/E assumptions around selinexor and the broader pipeline. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a mixed picture, with one price target increase following several cuts over a relatively short window.Mise à jour du récit • Apr 19
KPTI: Funding Uncertainty And Execution Risks Will Likely Cap Future Returns
Analysts have trimmed their average price target on Karyopharm Therapeutics by several dollars, citing updated views on discount rates, revenue assumptions and long term profit margins following recent Street research. Analyst Commentary Recent Street research shows several bearish analysts cutting their Karyopharm price targets by mid single digit to high single digit dollar amounts, pointing to revised assumptions on discount rates, revenue potential and long term margins.Mise à jour du récit • Apr 04
KPTI: Funding Strains And Execution Risks Will Likely Restrain Future Upside
The Street’s blended fair value estimate for Karyopharm has been trimmed by $1.00 to $5.00, as analysts fold in lower projected revenue growth, a slightly softer profit margin outlook, a higher discount rate, and updated P/E assumptions following recent target cuts from multiple firms. Analyst Commentary Recent Street research has tilted more cautious on Karyopharm, with multiple bearish analysts cutting price targets and reassessing the risk profile around execution, profitability, and the timing and scale of future revenue contributions.Mise à jour du récit • Mar 21
KPTI: Phase 1 Myelofibrosis Data Will Support 2026 Frontline Opportunity
Analysts have adjusted their price target for Karyopharm Therapeutics to $28, citing confidence in selinexor's differentiated mechanism of action, compelling Phase 1 data in myelofibrosis, and a projected peak revenue opportunity of $800m to $850m in frontline myelofibrosis, with further potential from multiple myeloma programs. Analyst Commentary Bullish Takeaways Bullish analysts see selinexor's differentiated mechanism of action as a key driver for long term value, supporting the $28 price target as they factor in a distinct clinical profile within myelofibrosis.
Mise à jour du récit • Mar 07
KPTI: Refreshed Revenue And Margin Outlook Will Support Bullish Repricing
Analysts have updated their price target on Karyopharm Therapeutics from $66.25 to $23.00, citing refreshed assumptions around revenue growth, profit margins, discount rate, and future P/E following recent bullish Street research. Analyst Commentary Bullish analysts are framing the reset in price target to $23.00 as part of a broader constructive view on Karyopharm Therapeutics, where refreshed modeling assumptions are more closely aligned with recent positive Street research.Mise à jour du récit • Feb 20
KPTI: Execution And Funding Risks Will Likely Cap Bullish Repricing
Analysts have raised their $6.00 price target for Karyopharm Therapeutics, citing slightly lower perceived risk, a modestly stronger revenue outlook, and a small increase in the expected future P/E as the key factors behind the update. Analyst Commentary Recent research commentary around Karyopharm Therapeutics has centered on how much risk investors should assign to the story, how sustainable the current revenue trajectory may be, and what a reasonable P/E might look like given execution needs ahead.Mise à jour du récit • Feb 06
KPTI: Lower Risk View Will Support 2026 Myelofibrosis Phase III Milestone
Analysts have modestly raised their price target on Karyopharm Therapeutics to US$15.33, citing a slightly lower required return and similar long term growth and margin assumptions that keep the fair value estimate steady. Analyst Commentary Recent Street research has focused on how the updated price target for Karyopharm Therapeutics lines up with its risk profile and execution needs, rather than materially changing long term growth or margin assumptions.Mise à jour du récit • Jan 23
KPTI: Extended Cash Runway Will Support 2026 Myelofibrosis Phase III Milestone
Narrative update on Karyopharm Therapeutics Analysts have nudged their fair value estimate for Karyopharm Therapeutics higher from US$14.67 to US$15.33, citing recent Street research that points to steady Xpovio sales, reduced financing overhangs, maintained MF timelines into March 2026, and updated price targets that reflect the latest financing transactions. Analyst Commentary Recent Street research highlights a mix of optimism around execution and caution around financing and valuation as analysts update their views on Karyopharm Therapeutics.Article d’analyse • Jan 11
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 1.1x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...Mise à jour du récit • Jan 09
KPTI: Financing Overhangs Will Likely Outweigh MF Timeline Support
Analysts have trimmed their 12 month price target on Karyopharm Therapeutics to US$19 from US$30, citing recent financing transactions. They also point to solid Xpovio sales and maintained MF timelines into March 2026 as support for the stock’s overall risk and reward profile.Mise à jour du récit • Dec 25
KPTI Extended Cash Runway Will Likely Be Outweighed By Dilution Risk
Analysts have cut their price target on Karyopharm Therapeutics to about $6 from roughly $8 per share, citing the impact of recent financing transactions on valuation. At the same time, extended cash runway, solid Xpovio sales and visibility into key 2026 myelofibrosis data support a still constructive risk and reward profile.Mise à jour du récit • Dec 11
KPTI: Extended Cash Runway Will Support Pivotal 2026 Myelofibrosis Phase III Readout
Analysts have modestly reduced their price targets on Karyopharm Therapeutics, trimming expectations from a prior average in the low $20s to the high teens. Recent financing transactions extend the cash runway into 2026 and also dilute near term upside, despite a solid outlook for Xpovio sales and key myelofibrosis data in 2026.Mise à jour du récit • Nov 27
KPTI: Extended Cash Runway Will Support Key Myelofibrosis Phase III Data
Analysts have lowered their price targets on Karyopharm Therapeutics, with reductions such as $19 from $30 and $6 from $8. They cite the impact of recent financing transactions while maintaining positive views on the company's risk profile and its cash runway extension, which is expected to support upcoming trial milestones.Mise à jour du récit • Nov 11
KPTI: Upcoming Myelofibrosis Phase III Readout Will Drive Future Opportunity
Karyopharm Therapeutics’ analyst fair value price target has decreased by $1.00 to $14.67. Analysts cite recent financing transactions and updated growth forecasts as key factors behind the revision.Mise à jour du récit • Oct 28
Extended Cash Runway Will Support Pivotal Phase III Clinical Milestones
Karyopharm Therapeutics' analyst price target has been reduced sharply from approximately $23.07 to $15.67 per share. Analysts cite the company’s recent strategic financing measures and updated projections following extended cash runway and upcoming clinical milestones.Mise à jour du récit • Oct 13
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics' analyst price target has been reduced from $8 to $6. This reflects analysts' views that, while strategic financing has extended the company's cash runway into Q2 2026, financial constraints and the timeline to key clinical trial readouts warrant a tempered outlook.Article d’analyse • Sep 11
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 65%
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shares have had a really impressive month, gaining 65% after a shaky...Mise à jour du récit • Aug 15
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92. What's in the News Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.Article d’analyse • Aug 14
US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results
NasdaqGS:KPTI 1 Year Share Price vs Fair Value Explore Karyopharm Therapeutics's Fair Values from the Community and...Article d’analyse • May 24
Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27%
Unfortunately for some shareholders, the Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) share price has dived 27% in the...Article d’analyse • May 22
Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet
Key Insights Karyopharm Therapeutics' Annual General Meeting to take place on 28th of May CEO Richard Paulson's total...
Nouveau récit • Apr 08
Phase III SENTRY And XPOVIO Approvals Will Secure Future Success
Positive trial outcomes in myelofibrosis and endometrial cancer could significantly boost revenue and redefine care standards.Article d’analyse • Dec 24
Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price Drop
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shareholders won't be pleased to see that the share price has had a very...Article d’analyse • Oct 01
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 0.7x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...Article d’analyse • Aug 09
Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) filed its second-quarter result this...Rendement pour les actionnaires
| KPTI | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 13.2% | 5.1% | -2.7% |
| 1Y | 132.6% | 36.7% | 18.6% |
Rendement vs Industrie: KPTI a dépassé le secteur US Biotechs qui a rapporté 36.7 % au cours de l'année écoulée.
Rendement vs marché: KPTI a dépassé le marché US qui a rapporté 18.6 % au cours de l'année écoulée.
Volatilité des prix
| KPTI volatility | |
|---|---|
| KPTI Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: KPTI n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de KPTI ( 11% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2008 | 228 | Richard Paulson | www.karyopharm.com |
Karyopharm Therapeutics Inc. est une société pharmaceutique au stade commercial qui découvre, développe et commercialise des médicaments dirigés contre l'exportation nucléaire pour le traitement du cancer et d'autres maladies aux États-Unis. La société découvre, développe et commercialise de nouvelles molécules et de petites molécules inhibitrices sélectives de l'exportation nucléaire (SINE) qui inhibent la protéine d'exportation nucléaire exportine 1 (XPO1). Ses principaux composés comprennent XPOVIO en association avec le bortezomib et la dexaméthasone pour le traitement des patients adultes atteints de myélome multiple ; en association avec la dexaméthasone pour le traitement des patients adultes atteints de myélome multiple récidivant ou réfractaire ; et pour le traitement des patients adultes atteints de lymphome diffus à grandes cellules B (DLBCL) récidivant ou réfractaire.
Karyopharm Therapeutics Inc. Résumé des fondamentaux
| KPTI statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$214.39m |
| Bénéfices(TTM) | -US$194.97m |
| Recettes(TTM) | US$151.12m |
1.5x
Ratio P/S-1.2x
Ratio P/ELe site KPTI est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| KPTI compte de résultat (TTM) | |
|---|---|
| Recettes | US$151.12m |
| Coût des recettes | US$130.79m |
| Marge brute | US$20.33m |
| Autres dépenses | US$215.30m |
| Les revenus | -US$194.97m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -8.60 |
| Marge brute | 13.45% |
| Marge bénéficiaire nette | -129.02% |
| Ratio dettes/capitaux propres | -111.7% |
Quelles ont été les performances à long terme de KPTI?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/26 03:19 |
| Cours de l'action en fin de journée | 2026/06/26 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Karyopharm Therapeutics Inc. est couverte par 20 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Colleen Kusy | Baird |
| Ying Huang | BofA Global Research |
| Harshita Polishetty | B. Riley Securities, Inc. |